The Journal of Infectious Diseases

@jidjournal.bsky.social did:plc:j7joregvysxlyvog2l3xewmp

In publication since 1904, JID is the premier global journal for original research on infectious diseases. JID is an official journal of @idsainfo.bsky.social

Bluesky’a katılma tarihi: 24 Ekim 2023

Takipçi: 6.861
Takip edilen: 1
Post: 1.158
Sıralamaya girdiği gün: 0

Özet

The Journal of Infectious Diseases (@jidjournal.bsky.social), 24 Ekim 2023 tarihinde katılan bir Bluesky kullanıcısı. 6.861 takipçisi var, 1 hesabı takip ediyor ve 1.158 post paylaştı.

Sıralama geçmişi

Bu hesabın postlarının Debya günlük listesine girdiği en iyi günler.

Bu hesap henüz günlük sıralamaya girmedi.

Son beğendiği postlar

Bluesky ağındaki herkese açık beğeniler.

IDSA@idsainfo.bsky.social2.11.2026 02:07
On IDSA’s & HIVMA’s Science Speaks blog: Learn more postnatal CMV infection in preterm infants, how rates of IPD since the COVID-19 pandemic shape vaccine recommendations and other research in @jidjournal.bsky.social ready to inform clinical practice. https://bit.ly/4BBski2
Postu göster
IDSA@idsainfo.bsky.social29.10.2026 15:32
On IDSA’s & HIVMA’s Science Speaks blog: Check out insights from the editors of a new, ongoing series of articles in @cidjournal.bsky.social highlighting how experienced clinicians deploy problem-solving skills to navigate complex cases. https://bit.ly/48mkxr0
Postu göster
IDSA@idsainfo.bsky.social10.10.2026 00:43
What happens when an antiviral works by causing mutations? In a new Let’s Talk ID episode, JID Deputy Editor Jonathan Li, MD, FIDSA talks the science behind molnupiravir and a recent paper that raised questions about its potential effects in mammalian cells. Watch: www.idsociety.org/multimedia/p...
Postu göster
IDSA@idsainfo.bsky.social8.10.2026 00:51
On IDSA’s & HIVMA’s Science Speaks: Learn more about the efficacy of switching to doravirine/islatravir, how immunocompromised individuals hospitalized with COVID-19 remain at increased mortality risk and other research in @jidjournal.bsky.social to inform clinical practice. https://bit.ly/4AYYFzi
Postu göster
IDSA@idsainfo.bsky.social1.07.2026 16:27
On IDSA’s & HIVMA’s Science Speaks blog: Learn about the poor antimalarial efficacy of IPTp-SP, how starting HIV treatment in early life can significantly reduce the size of the HIV reservoir and other new research in JID that’s ready to inform clinical practice. https://bit.ly/3SI2GGA
Postu göster

Daha fazlası için üye girişi yap

Blokladığı hesaplar

Bluesky’da bloklar herkese açık kayıtlardır.

Bu hesap kimseyi bloklamıyor.